Last updated: February 15, 2026
mmary:
Finland’s patent system adheres to European Patent Office (EPO) standards aligned with the European Patent Convention (EPC). Biopharmaceutical patents face specific challenges: novelty, inventive step, and industrial applicability are scrutinized, especially against prior art and ethical considerations. Patentability depends on substantive criteria, enforceability hinges on clear claims and standard legal defenses, and claim scope is influenced by limitations on biological material and methods.
What Are the Patentability Requirements for Biopharmaceuticals in Finland?
Novelty and Inventive Step
Biopharmaceutical patents require a novel invention with an inventive step.
- Novelty is assessed against prior art, including existing patents, scientific literature, and publicly available data.
- Inventive step considers whether the invention would be obvious to someone skilled in the field.
- Specific to biopharma, prior disclosures of biological material, sequences, and methods can negate novelty or inventive step.
Industrial Applicability
The invention must have a specific, credible industrial application, which is generally straightforward for pharmaceuticals but may be contested if, for example, the biological activity cannot be reliably demonstrated.
Excluded Subject Matter
Under Finnish law and EPC standards, the following are excluded from patentability:
- Discoveries, including naturally occurring biological materials not isolated or purified.
- Methods of treatment of the human or animal body (methods of medical treatment are generally excluded, but product claims can be patentable).
- Methods of surgical or diagnostic methods.
Biological Material and Sequence Claims
Biopharmaceutical inventions often involve biological sequences.
- Patent applications can claim isolated biological materials, provided they are sufficiently characterized.
- Claims covering natural substances or unmodified biological material are typically not patentable unless isolated, purified, and characterized substantially differently from their natural state.
What Are the Challenges for Enforceability of Biopharmaceutical Patents in Finland?
Claim Clarity and Support
- Strict standards for claim clarity; claims must be clear, concise, and supported by the description.
- Vagueness or ambiguous claims are grounds for rejection or invalidation.
Biological Material and Method Claims
- Biological materials must be described sufficiently to enable third parties to work with them.
- Method claims, especially for medical or diagnostic procedures, can face limitations due to exclusions on patenting methods of treatment.
Legal Defenses and Patent Enforcement
- Common defenses include arguing the invention lacks novelty or inventive step or that the patent claims extend beyond what was disclosed.
- Challenges can be based on prior art or procedural deficiencies.
- Finnish courts and the EPO emphasize thorough documentation and enablement.
How Is Claim Scope Defined and Limited in Finnish Patent Practice for Biopharmaceuticals?
Biological and Functional Claim Limitations
- Claims often specify biological sequences, biological functions, or specific processes.
- Purely functional claims may be limited unless they are supported by specific descriptive embodiments.
Use and Method Claims
- Use claims cover specific applications of biological compounds, e.g., a particular disease treatment.
- Method claims for manufacturing or medical use are more difficult to patent if they involve medical treatments, aligned with EPC and Finnish practice, due to exclusions on surgical/method-of-treatment claims.
Claims Covering Natural Biological Material
- Claims cannot extend to naturally occurring biological material unless it has been isolated, purified, and characterized with new properties.
- Combination claims that include both biological material and specific methods are permissible if supported.
Claim Drafting Strategies
- Focus claims on the isolated biological material with specific structural features.
- Include method claims where possible, with explicit steps and conditions.
- Use functional language supported by detailed descriptions but avoid overly broad scope.
- Clarify the specific use, manufacturing process, or therapeutic application.
Summary of Key Regulatory and Patent Data
| Aspect |
Details |
References |
| Patentability criteria |
Novelty, inventive step, industrial applicability |
European Patent Convention, Finnish Patent Act |
| Biological material claims |
Must be isolated, characterized, not naturally occurring |
[1] |
| Excluded subject matter |
Medical methods, discoveries, natural products |
[2] |
| Enforcement |
Clarity, support, enablement critical |
EPO Guidelines, Finnish Court Rulings |
| Claim scope |
Limited by biological characterization and specific applications |
[3] |
Key Takeaways
- Finland applies EPC standards, requiring clear, supported claims aligned with inventive step and novelty.
- Biological material claims need proper characterization; naturally occurring materials are generally not patentable unless isolated and purified.
- Medical method claims face restrictions; claims should specify compounds, uses, or manufacturing methods to improve enforceability.
- Enforcement depends on clarity, scope, and demonstration of patent infringement.
- Patent drafting should tightly define biological sequences, functions, or processes to avoid invalidation.
FAQs
1. Can naturally occurring biological substances be patented in Finland?
Only if they are isolated, purified, and characterized with new properties. Simply discovering a natural substance does not qualify.
2. Are medical methods patentable in Finland?
Generally, no. Patents cannot cover methods of medical treatment. Claims focus on compounds, compositions, or manufacturing methods.
3. What supports enforceability of biopharmaceutical patents?
Clear, supported claims with detailed descriptions, testing data, and biological characterization strengthen enforcement.
4. How do claim scope limitations affect patent protection?
Overly broad claims risk invalidation; specific, well-supported claims offer better protection.
5. Are there specific Finnish or EPC provisions impacting patentability?
Yes. Finnish law aligns with EPC Articles 53(c) and 54–56, governing exclusions, novelty, and inventive step in biotech patents.
Citations:
[1] Finnish Patent Act, 16 June 1967/550 (Amended).
[2] European Patent Convention, Articles 52–57.
[3] EPO Guidelines for Examination, Part G, Chapter VI.
